Mirriad shares jump as much as 18% after £346,000 tax credit boosts cash position

Mirriad Advertising received a £346,000 R&D tax credit from HMRC relating to the year ended 31 December 2024, boosting its cash position to approximately £1.275m. The non-dilutive payment, tied to its virtual product-placement technology, triggered an early intraday share rise of up to 18% before settling at 0.006p (up 9%), providing a modest liquidity uplift for the small-cap group.

Analysis

Market structure: The £346k R&D credit is a positive but immaterial change to Mirriad's (AIM:MIRI / OTCQX:MMDDF) fundamentals — cash now ~£1.275m, which likely extends runway by only a few months. Winners are short-term retail/speculators and R&D-heavy microcap techs who intermittently benefit from non-dilutive credits; losers are holders of illiquid AIM microcaps facing dilution risk if funding is required. Cross-asset impact is negligible for bonds, FX and commodities; expect small-cap AIM index flows and option illiquidity to move intra-day prices, not macro markets.

Risk assessment: Tail risks include rapid dilution via equity raise (probability high within 3–9 months if no revenue acceleration), regulatory scrutiny of embedded advertising/consumer privacy (medium probability, high impact) and failed platform integrations. Immediate (days) effect = sentiment spike and thin-book volatility; short-term (weeks–months) = funding event risk and burn-rate revelation; long-term (quarters–years) = dependent on contract wins and scalable CPM economics. Hidden dependency: revenue realization requires content partner deals and platform SDK integrations — absence of either kills growth.

Trade implications: Direct play = tiny, disciplined speculative long in AIM:MIRI sized 0.1–0.25% NAV with hard stop; avoid leverage due to illiquidity and near-term funding risk. Relative trade = overweight large-cap ad/tech incumbents (GOOGL, ticker: NASDAQ:GOOGL) or LON:WPP to capture structural ad recovery while underweight AIM microcaps. Options: prefer defined‑risk call spreads on large-cap ad tech (3‑month buy 5% OTM / sell 20% OTM) rather than illiquid Mirriad derivatives.

Contrarian angles: Consensus treats the R&D credit as a material cash cure — it is not; price reaction is likely overdone and short‑lived absent commercial milestones. Historical parallel: small R&D rebates for loss-making micros frequently precede fundraising and dilution, not turnaround. Unintended consequence: retail chase could tighten float then crater on a modest equity raise; price is fragile to any negative corporate update.

Key Decisions for Investors

• Establish a speculative long position in Mirriad (AIM:MIRI / OTCQX:MMDDF) sized 0.1–0.25% of NAV at current levels (~0.006p), set a hard stop-loss at -50% and a profit-taking zone at +100–200%; time horizon 1–3 months pending cash-runway disclosure.
• Overweight large-cap ad/tech exposure: add 1–2% NAV to LON:WPP or NASDAQ:GOOGL via cash or a 3‑month call spread (buy 5% OTM, sell 20% OTM) to capture ad-revenue rebound with defined risk; exit or roll at 90 days.
• Trim or avoid AIM small-cap ad-tech positions: reduce exposure by 25–50% vs benchmark immediately to lower dilution and liquidity risk; only re-enter after company discloses ≥12 months runway or signed revenue contracts covering next 12 months.
• Set immediate alerts for Mirriad: (a) any fundraising announcement (react: sell/short into >20% dilution), (b) material commercial contracts or platform integrations (buy/add only if contracts provide >£1m ARR or multi-year revenue visibility).